Why is Brawn Biotech falling/rising?

As of 01-Jul, Brawn Biotech Ltd's stock price is currently at 18.35, reflecting an increase of 0.87 or 4.98%. The stock has been on an upward trend, gaining for the last three days with a total return of 13.55% during this period. Additionally, it has outperformed its sector by 5.84%. However, despite these short-term gains, the company faces significant challenges, including operating losses and a weak long-term fundamental strength, as evidenced by a negative annual growth rate in net sales and operating profit over the past five years. The stock's performance has been hindered by negative EBITDA and a poor ability to service its debt, which may contribute to investor caution despite recent price increases.
In the broader market context, Brawn Biotech's short-term performance of +7.94% over the past week significantly outpaces the Sensex, which has only increased by 2.00% during the same period. However, the stock has underperformed over the longer term, with a year-to-date decline of -13.89% compared to the Sensex's gain of +7.11%. This disparity highlights the stock's volatility and the challenges it faces in regaining investor confidence, especially given its substantial underperformance over the past year relative to the broader market.